JP2003510286A5 - - Google Patents

Download PDF

Info

Publication number
JP2003510286A5
JP2003510286A5 JP2001526191A JP2001526191A JP2003510286A5 JP 2003510286 A5 JP2003510286 A5 JP 2003510286A5 JP 2001526191 A JP2001526191 A JP 2001526191A JP 2001526191 A JP2001526191 A JP 2001526191A JP 2003510286 A5 JP2003510286 A5 JP 2003510286A5
Authority
JP
Japan
Prior art keywords
ruhi
emil
thio
monkey
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001526191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510286A (ja
Filing date
Publication date
Priority claimed from US09/408,436 external-priority patent/US6149915A/en
Application filed filed Critical
Publication of JP2003510286A publication Critical patent/JP2003510286A/ja
Publication of JP2003510286A5 publication Critical patent/JP2003510286A5/ja
Pending legal-status Critical Current

Links

JP2001526191A 1999-09-29 2000-09-21 糖尿病性腎症および微量アルブミン尿症の治療 Pending JP2003510286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/408,436 1999-09-29
US09/408,436 US6149915A (en) 1999-09-29 1999-09-29 Treatment of diabetic nephropathy and microalbuminuria
PCT/US2000/025783 WO2001022981A1 (en) 1999-09-29 2000-09-21 Treatment of diabetic nephropathy and microalbuminuria

Publications (2)

Publication Number Publication Date
JP2003510286A JP2003510286A (ja) 2003-03-18
JP2003510286A5 true JP2003510286A5 (enExample) 2007-11-08

Family

ID=23616291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526191A Pending JP2003510286A (ja) 1999-09-29 2000-09-21 糖尿病性腎症および微量アルブミン尿症の治療

Country Status (7)

Country Link
US (3) US6149915A (enExample)
EP (1) EP1218020A1 (enExample)
JP (1) JP2003510286A (enExample)
CN (1) CN1387439A (enExample)
AU (1) AU771275B2 (enExample)
CA (1) CA2386000A1 (enExample)
WO (1) WO2001022981A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
CN102579460B (zh) * 2003-12-30 2015-04-29 麦仁斯有限公司 用增强代谢活性的丹参衍生物治疗肥胖和代谢综合症
US8029829B2 (en) 2005-02-03 2011-10-04 Taiyo Kagaku Co., Ltd. Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy
CN100341581C (zh) * 2005-07-29 2007-10-10 上海第二医科大学附属第九人民医院 一种丹酚酸b有效干预口腔癌动物模型的方法
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
WO2007102451A1 (ja) * 2006-03-07 2007-09-13 Nippon Shinyaku Co., Ltd. 育毛剤
US20100174097A1 (en) * 2007-03-28 2010-07-08 Man Kil Jung Method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
WO2011061749A2 (en) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
CN102550916A (zh) * 2012-02-04 2012-07-11 王姗思 一种用于糖尿病肾病的食品
CN102614267A (zh) * 2012-04-24 2012-08-01 许风国 一种治疗糖尿病肾病的中药组合物及其制备方法
CN103830496A (zh) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 一种辅助降糖的组合物
CN104974119B (zh) * 2014-04-01 2018-10-19 中国科学院上海药物研究所 一种高纯度丹酚酸b镁及其制备方法
CN104547498A (zh) * 2014-12-31 2015-04-29 黎细乐 一种中药组合物的新用途
US20160361288A1 (en) * 2015-06-10 2016-12-15 Postech Academy-Industry Foundation Pharmaceutical compositions for preventing or treating diabetic nephropathy comprising the activity inhibitor of tenc1
CN105311413A (zh) * 2015-11-18 2016-02-10 暨南大学 治疗糖尿病肾病的含有艾叶的中药组合物及其制备方法
CN107551172A (zh) * 2017-10-26 2018-01-09 马雪英 一种治疗肾病综合症的药物及其制备方法
CN110215449A (zh) * 2019-05-13 2019-09-10 中国科学院长春应用化学研究所 紫草酸在抑制胰岛素淀粉样多肽聚集中的应用
CN112190646B (zh) * 2020-11-19 2021-12-28 首都医科大学附属北京中医医院 一种治疗糖尿病肾病的中药组合物及其制备方法
CN112569313B (zh) * 2020-12-28 2022-02-22 贵州三力制药股份有限公司 治疗肾病的中药组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268682A (ja) * 1988-04-21 1989-10-26 Minofuaagen Seiyaku Honpo:Goushi 腎機能改善剤及びリソスペルミン酸塩の製造方法
US5358962A (en) * 1993-04-22 1994-10-25 Minophagen Pharmaceutical Company Antihypertensive method
JP3638967B2 (ja) * 1993-06-03 2005-04-13 日本ケミカルリサーチ株式会社 ネフローゼ症候群及び肝障害症状の寛解剤
JP3161882B2 (ja) * 1993-06-03 2001-04-25 日本ケミカルリサーチ株式会社 丹参由来多糖類、その製造法および用途
US5547945A (en) * 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria

Similar Documents

Publication Publication Date Title
JP2003510286A5 (enExample)
Beeh et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Abramowitz et al. Effects of oral sodium bicarbonate in patients with CKD
Sharma et al. Effect of aging on respiratory system physiology and immunology
Fonseca et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial
Singh et al. Influence of pranayamas and yoga-asanas on serum insulin, blood glucose and lipid profile in type 2 diabetes
Colette et al. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes
Howes et al. Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes
Hansen et al. Effect of administration of oral contraceptives on the synthesis and breakdown of myofibrillar proteins in young women
WO2003090671A3 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
Perez et al. Hypoxia stress test reveals exaggerated cardiovascular effects in hypertensive rats after exposure to the air pollutant acrolein
Neder et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD
Hosseinpour et al. Efficacy of exercise training-based cardiac rehabilitation programmes after transcatheter aortic valve implantation: A systematic review and meta-analysis
Möhrenschlager et al. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique
BRPI0416248A (pt) métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina
Rennie et al. Reliability of results and interpretation of measures of 3-methylhistidine in muscle interstitium as marker of muscle proteolysis
Dugas The development and validation of a field test to estimate aerobic endurance in older adults
Hauber et al. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes
Smith et al. Impact of varying physical activity levels on airway sensitivity and bronchodilation in healthy humans
Yokoyama et al. Acute rhabdomyolysis associated with troglitazone.
Han et al. The effects of the physical activity program on body composition, depression and risk factors of dementia in the elderly women
Becker Family systems and compliance with medical regimen.
JPS5992948U (ja) 計算尺
Preskorn Outliers on the dose-response curve: How to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry
Johnson A regulatory view